Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Sleep Disor Treat Care Vol: 4 Issue: 3
Effects of Mandibular Advancement Devices on Sleep, Blood Pressure and Jaw Functions in Patients with or without Diabetes
| Lillian Marcussen1*, Jan Erik Henriksen2, Peter Svensson3,4 and Torben Thygesen1 | |
| 1Department of Oral and Maxillofacial Surgery, Odense University Hospital,Denmark | |
| 2Department of Endocrinology, Odense University Hospital, Denmark | |
| 3Department of Dentistry, Aarhus University, Denmark | |
| 4Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden | |
| Corresponding author : Lillian Marcussen Department of Oral and Maxillofacial Surgery, Odense University Hospital, Sonder Boulevard 29, 5000 Odense C, Denmark Tel: +004565413475; Fax:+00456614 82 26 E-mail: Lillian.Marcussen@rsyd.dk |
|
| Received: June 29, 2015 Accepted: October 20, 2015 Published: October 25, 2015 | |
| Citation: Marcussen L, Henriksen JE, Svensson P, Thygesen T (2015) Effects of Mandibular Advancement Devices on Sleep, Blood Pressure and Jaw Functions in Patients with or without Diabetes. J Sleep Disor: Treat Care 4:3. doi:10.4172/2325-9639.1000162 |
Abstract
Severity of obstructive sleep apnea (OSA) has two main
components: severity of daytime sleepiness and apnea hypopnea index (AHI) in addition to adjacent health complications. We investigated the effect of custom-made Mandibular Advancement Devices (MADs) on breathing pattern parameters (including apneahypopnea index), blood pressure, daytime sleepiness (Epworth score) and temporomandibular disorders (TMD) in a randomized crossover trial at the Department of Oral and Maxillofacial Surgery, Odense University Hospital, on consecutively treated patients diagnosed with snoring or sleep apnea. Continuous registrations of outcome variables were performed; patients underwent diagnostic cardio-respiratory monitoring before and after 3 months’ MAD
therapy, and results obtained in patients before MAD therapy were compared with those obtained after MAD therapy. Measurements with and without MAD were compared using Student’s t-test or Wilcoxon signed rank test, and mixed-model analyses was performed to analyze repeated measurements and adjusting for sleep apnea severity, type 2 diabetes, body-mass-index, sex and age. A total of 44 patients (31 men; 13 women, aged 50 ± 13 years, BMI 31 ± 5.6, diabetic n=18; non-diabetic n=26) completed the
trial. The apnea-hypopnea index (AHI) reduced from 15.8 ± 17.4 without MAD to 6.2 ± 9.8 events/h with MAD (P<0.001). After 6 months without therapy compared with 6 months’ MAD therapy, mean systolic blood pressure decreased from 135 ± 15 to 132 ± 15 mm/Hg (P=0.02) and Epworth score decreased from 10 ± 5 to 6 ± 3 (P<0.001). The occurrence of TMD diagnoses did not increase, no patients discontinued therapy due to TMD, and there were no interactions between diabetes status or obstructive sleep apnea severity evident for any outcome parameter.
Conclusions: The present study confirmed MAD therapy to be a relevant treatment option without significant side effects on jaw function in patients with high as well as low AHI, and in diabetic as well as non-diabetic patients.
